

This listing of claims will replace all prior versions, and listings of claims, in the application:

Listing of Claims:

1-14. (canceled)

15. (currently amended) A composition comprising (i) a non replicative recombinant adenoviral vector wherein said non replicative recombinant adenoviral vector comprises a heterologous polynucleotide sequence encoding a polypeptide, which polynucleotide sequence is inserted into a deleted E1 region of said non replicative recombinant adenoviral vector and is under the control of ~~a promoter selected from the promoter contained in the Long Terminal Repeat of Rous Sarcoma Virus, the promoter of the IE gene of cytomegalovirus, the Mouse Mammary Tumor Virus inducible promoter and the metallothionine promoter~~ wherein said polypeptide is expressed *in vivo* in muscle cells for at least 90 days after administration of said composition and is distributed throughout the muscle mass;
and (ii) a pharmaceutically acceptable carrier.

16. (canceled)

17. (previously added) The composition according to claim 15, wherein said polynucleotide sequence encodes a polypeptide having thrombolytic properties.

18. (previously added) The composition according to claim 15, wherein said polynucleotide sequence encodes a polypeptide which is all or part of a dystrophin gene product.

19. (previously added) The method according to claim 15, wherein said polynucleotide sequence encodes a polypeptide which is a β -galactosidase gene product.

20-21. (canceled)
